Acerbi, I., Cassereau, L., Dean, I., Shi, Q., Au, A., Park, C., et al
Yaghi S, Elkind MS
It used to run, somewhere between 2-2.5 percent, in the first part of this year
doi: 10.3389/fcvm.2025.1661563 Received 21 July 2025 Accepted 09 October 2025 Published 29 October 2025 Volume 12 - 2025 Edited by Manuel Gmez-Guzmn, University of Granada, Spain Reviewed by Manuel Snchez Santos, University of Granada, Spain Javier Molen Moya, University of Mnster, Germany Updates Copyright 2025 Nzobokela, Muchaili, Mwambungu, Masenga and Kirabo
Genetic or pharmacological blockade of GIP, GLP-1, or PPAR signaling markedly reduced metabolic effects, supporting a combined incretinPPAR mechanism of action
Pre vechi: 160,50 LEI Pre: 112,35 LEI - 30% Pudra proteica cu extracte vegetale si aroma de ciocolata